Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Summary of measurement approaches for two assessments

From: Optimizing immune-related tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab?

  irRC simulating RECIST1.0 irRC simulating RECIST1.1
Number of target lesions Up to 5 per organ, up to 10 in total Up to 2 per organ, up to 5 in total
Measurable lesions ≥10 mm in the longest diameter for all lesions ≥10 mm in the longest diameter for all lesions except for lymph nodes
  ≥15 mm in short axis for nodes
Measurement of each lesion The longest diameter for all target lesions The longest diameter for non-nodal lesions, short axis for lymph nodes
New lesions The presence of new lesion does not define progression Same as irRC simulating RECIST1.0 except:
The measurements of the new lesion (s) are included in the sum of the measurements A lymph node has to be ≥15 mm in short axis to be a measurable new lesion and its short axis measurement is included in the sum
Up to 5 new lesions per organ, up to 10 new lesions in total can be added to measurements Up to 2 new lesions per organ, up to 5 new lesions in total can be added to the measurements